Emerging First-Line Treatment Options for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) - Episode 9

A Look Towards the Future of ESCC

,

Closing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.

EP. 1: Trends in ESCC Incidence and Observations from Clinical Practice
EP. 2: Approaches to Biomarker Testing for ESCC
EP. 3: The Impact of Biomarker Results on Prognosis and Treatment Decision-Making
EP. 4: First-Line Options for Advanced/Metastatic Disease
EP. 5: Insights on ESCC First-Line Treatment Selection
EP. 6: RATIONALE-306 Data on Tislelizumab in ESCC
EP. 7: The Potential Impact of Tislelizumab on First-Line ESCC Treatment
EP. 8: Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers
Now Viewing
EP. 9: A Look Towards the Future of ESCC

Related Content:

Emerging First-Line Treatment Options for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)OncLive News Network®
Key Takeaways for Concurrent Biomarker Testing in NSCLC
Overcoming Barriers to NSCLC Biomarker Testing
Challenges of NSCLC Biomarker Testing in Clinical Practice